Non-small cell lung cancer
Non-small cell lung cancer (NSCLC) is a major biological and clinical category of lung cancer that is investigated through its histologic, molecular, and treatment-response characteristics.
Non-small cell lung cancer (NSCLC) is a major biological and clinical category of lung cancer that is investigated through its histologic, molecular, and treatment-response characteristics. Recent work has focused on adenocarcinoma and adenocarcinoma of the lung, actionable alterations involving the EGFR (EGFR), and less common molecular contexts such as NRAS-mutant disease. Molecular profiling approaches include massively parallel sequencing, proteomics, and analysis of small bronchoscopic tumor specimens.
NSCLC research also encompasses systemic and targeted therapies, including Epidermal Growth Factor Receptor Tyrosine Kinase Inhibitors and other tyrosine-kinase inhibitors such as osimertinib and lazertinib, as well as immune checkpoint inhibitors directed toward pathways involving the CD274 molecule. Important clinical measures include objective response rate, progression-free survival, and overall survival. Other active areas include central nervous system involvement, tumor microenvironment biology, drug delivery, cytotoxicity, and apoptosis.
Rebuilt from PubMed 18 Sept 2026 · no new papers today
Where the papers sit
10 papers study non-small cell lung cancer directly. The themes below are drawn from those 10.
-
NSCLC Translational Research : Omics-based mechanism studies, CD276 CAR-T therapy, bronchoscopic molecular profiling, and early-warning prediction all seek more precise NSCLC treatment and detection. Cytotoxicity, apoptosis, lipid metabolism, and functional assays recur, but the approaches remain disparate. 4 papers · 40%
-
NSCLC Treatment and Survival : EGFR-directed therapy is extending toward intracranial disease, with lazertinib showing CNS activity after prior EGFR TKI exposure. Experimental NRAS-mutant delivery and NF1-associated lung disease also appear, leaving no single therapeutic direction. 3 papers · 30%
-
NSCLC Surgical Outcomes : Minimally invasive and robotic resection are being assessed against 90-day mortality and survival, while recurrence definitions and electronic-record reconstruction sharpen outcome measurement. The focus is surgical quality and post-resection prognosis in resectable NSCLC. 3 papers · 30%
Recent Findings on Non-small cell lung cancer
NSCLC Translational Research: Inonotus obliquus polysaccharides (IOPs) suppressed NSCLC proliferation and tumor growth while altering lipid metabolism, nuclear processes, and the tumor immune microenvironment in experimental models 42532236Jul. p40-H3BBz CAR T-cells targeting CD276 increased IL-23 secretion, cytotoxicity, T-cell infiltration, and tumor growth inhibition without significant major-organ toxicity 42262195Jun. RNAlater-preserved bronchoscopic specimens yielded DNA, RNA, and proteins for integrated profiling, with complete concordance for mutation testing and good concordance for histological classification 42509268Jul. The mSTOP model identified nonresponders to immune checkpoint inhibitors with an 84.8% positive predictive value, which increased to 95.7% when combined with CT imaging 42054314Apr. IOPs still require further validation, whereas mSTOP has progressed toward real-time clinical implementation through an integrated ICT and quality-control system 42532236Jul42054314Apr.
Advanced Lung Cancer Treatment: Patients with EGFR-mutated NSCLC and CNS involvement achieved intracranial responses with lazertinib after prior EGFR tyrosine kinase inhibitor exposure, including a 97.8% intracranial disease control rate 42670582Aug. Leptomeningeal metastases predicted inferior overall survival and intracranial progression-free survival, while outcomes did not significantly differ by T790M status 42670582Aug. In NRAS-mutant lung carcinoma models, N-methylated YKWYYRGAA-decorated nano-chitosan improved intracellular delivery and induced mitochondria-mediated apoptosis through ROS activation and FasL-linked death 42230031Jun. The P2 formulation also suppressed mTOR/MAPK signalling, drug-resistance markers, and epithelial-mesenchymal transition, whereas the unmethylated and dimethylated formulations were limited at the membrane interface 42230031Jun. A patient with NF1-associated diffuse lung disease and mediastinally invasive NSCLC achieved a sustained complete response for 10 years despite radiation pneumonitis and bacterial pneumonia 42481140Jul.
NSCLC Surgical Outcomes: NSCLC resection in England became more common from 2015 to 2023, while segmentectomy and minimally invasive surgery increased, pneumonectomy declined, and 90-day mortality fell 42749376Sep. Centre-level practice remained heterogeneous, with wide variation in segmentectomy for small stage IA tumors and robotic-assisted thoracoscopic surgery adoption 42749376Sep. Recurrence within 12 months after resection marked worse post-recurrence survival than later recurrence, supporting 12 months as a clinically useful threshold 42747627Sep. A Japanese real-world cohort reproduced atezolizumab progression-free survival from the OAK trial using manually reviewed unstructured electronic medical records, although hospital-transfer losses prevented reliable overall survival estimation 42489799Jul. These findings link improving perioperative outcomes with persistent variation in surgical implementation and continuing efforts to standardize recurrence and real-world survival measurement.
Written from 10 PubMed abstracts, each one cited by PMID above. Published: 2026-09-02. Last written: 2026-09-18 by GPT. Drafted by language models from published abstracts; not medical advice.